Alx oncology and quantum leap healthcare collaborative™ announce first patient dosed in the i-spy-p1 trial in breast cancer

South san francisco, calif., march 13, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, and quantum leap healthcare collaborative (“quantum leap”) today announced that the first patient has been dosed in the i-spy-p1-trial for the treatment of patients with unresectable or metastatic her2-positive and her2-low breast cancer. sponsored by quantum leap, this phase 1 (open-label), multi-center study arm will investigate evorpacept, a cd47 blocker, in combination with enhertu® (fam-trastuzumab deruxtecan-nxki), a her2 directed antibody-drug conjugate (“adc”), to determine the safety, tolerability and efficacy of this drug combination.
ALXO Ratings Summary
ALXO Quant Ranking